$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Tepotinib latest price in 2024
2026-02-01 22:25:32
Check Details
Tepotinib domestic launch time
2026-02-01 22:25:32
Check Details
Is tepotinib included in domestic medical insurance? How much does a box cost?
2026-02-01 22:25:32
Check Details
How much does a box of tepotinib cost in China?
2026-02-01 22:25:32
Check Details
Aceminib: Indications, Dosage, Contraindications, Side Effects and Pill Interactions
2026-02-01 22:25:32
Check Details
How effective is aximini as a single agent? Is it outstanding?
2026-02-01 22:25:32
Check Details
Aceminib for third-line treatment of chronic myelogenous leukemia
2026-02-01 22:25:32
Check Details
Aceminib continues to demonstrate good remission effects in patients with chronic myelogenous leukemia at 48-week follow-up
2026-02-01 22:25:32
Check Details
Aceminib is more effective and safer for patients with chronic phase CML
2026-02-01 22:25:32
Check Details
Is Asiminib useful for chronic myelogenous leukemia?
2026-02-01 22:25:32
Check Details
Can Mobotinib be purchased in the country?
2026-02-01 22:25:32
Check Details
How much does moboxetinib succinate capsules cost?
2026-02-01 22:25:32
Check Details
1
2
...
779
780
781
782
783
784
785
...
10223
10224
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
2
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
3
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
4
Elagolix Side Effects and Safety Guide
5
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
6
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
7
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
8
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
9
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
10
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
11
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
12
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC